The International Advisory Panel (IAP) plays a critical advisory role as ACE (i) conducts health technology assessment (HTA) on treatments and technologies, and (ii) strengthens its guidance development methodology and builds its evidence implementation efforts to support clinicians in practising evidence-based medicine, to achieve cost-effective and appropriate healthcare in Singapore. The Panel will also offer a global perspective, which will help us keep abreast of relevant developments and initiatives internationally. IAP members are appointed for a 2-year term starting from 1 Mar 2021 to 28 Feb 2023.
The IAP's terms of reference are to advise ACE on the following areas:
- Critique, recommend improvements and advise on ACE’s workplan and initiatives (e.g. drug and medical technology evaluation methods and processes, manufacturer submission’s methods and process manual, guidance development methods and processes) to keep abreast with international best practices;
- Provide insights on emerging trends and developments in HTA, and/or guidance development and evidence implementation;
- Share approaches to guide Singapore’s implementation efforts to build capabilities in HTA, guidance development and execution of evidence-based practice; and conduct training for ACE staff in these areas; and
- Connect ACE to international networks in the area of HTA, guidance development and/or evidence implementation.
The ACE Council was formed as an advisory body to steer the Agency’s development to drive appropriate healthcare in Singapore. Led by an eminent senior clinician, the Council comprises well-respected senior medical specialists and professionals across a range of disciplines.
The combined expertise and experience of Council members in medicine, research and academia, health economics, legal, social policy and government policy, present a holistic perspective to guide the Agency's development.
The Council's terms of reference:
- To advise the Ministry on the development of initiatives to promote the use of evidence-based, safe and cost-effective medicines in public hospitals and institutions (PHIs).
- To develop strategies to harmonise formulary drugs across PHIs where appropriate and to facilitate timely listing of subsidised drugs.
- To advocate appropriate use of medicines by:
- promoting the use of generic alternatives (including biosimilars) of medicines, where available;
- working collaboratively with stakeholders to influence appropriate use of medicines in the PHIs (including compliance with ACE Guidance, where available);
- facilitating the sharing of national drug utilisation data to provide PHIs with appropriate benchmark for reviewing each PHI’s practices.